Evidence map›Paper›PMID 34270823›Full record

ArticleJournal of leukocyte biology2022

miR-181c regulates MCL1 and cell survival in GATA2 deficient cells.

Weixin Wang, Rui Chen, Stephenie Droll, Emily Barber, Layla Saleh, Meghan Corrigan-Cummins, Megan Trick, Vollter Anastas, Nga Voong Hawk, Zhen Zhao and 5 more

Open access · greenAbstract read
In one paragraph

Article in Journal of leukocyte biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. GATA2 Mediates Macrophage Proliferation During Atherosclerosis.Journal of the American Heart Association · 2025
    Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 4 countries.

Weixin WangDepartment of Laboratory Medicine, National Institutes of Health (NIH) Clinical Center, Bethesda, Maryland, USA.
Rui ChenDepartment of Laboratory Medicine, Beijing Tong-Ren Hospital, Capital Medical University, Beijing, China.
Stephenie DrollDepartment of Laboratory Medicine, National Institutes of Health (NIH) Clinical Center, Bethesda, Maryland, USA.
Emily BarberDepartment of Laboratory Medicine, National Institutes of Health (NIH) Clinical Center, Bethesda, Maryland, USA.
Layla SalehDepartment of Laboratory Medicine, National Institutes of Health (NIH) Clinical Center, Bethesda, Maryland, USA.
Meghan Corrigan-CumminsDepartment of Laboratory Medicine, National Institutes of Health (NIH) Clinical Center, Bethesda, Maryland, USA.
Megan TrickDepartment of Laboratory Medicine, National Institutes of Health (NIH) Clinical Center, Bethesda, Maryland, USA.
Vollter AnastasDepartment of Laboratory Medicine, National Institutes of Health (NIH) Clinical Center, Bethesda, Maryland, USA.
Nga Voong HawkExperimental Transplantation and Immunology Branch, National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA.
Zhen ZhaoDepartment of Laboratory Medicine, National Institutes of Health (NIH) Clinical Center, Bethesda, Maryland, USA.
Donald C VinhLaboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA.
Amy HsuLaboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA.
Dennis D HicksteinImmune Deficiency Cellular Therapy Program, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA.
Steven M HollandLaboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA.
Katherine R CalvoDepartment of Laboratory Medicine, National Institutes of Health (NIH) Clinical Center, Bethesda, Maryland, USA.
National Institutes of Health Clinical Center · USNational Institute of Allergy and Infectious Diseases · USBeijing Tongren Hospital · CNCenter for Cancer Research · USCornell University · USMansoura University · EGMcGill University Health Centre · CANational Cancer Institute · US

Funding

Hematopoietic Stem Cell Transplant for Immunodeficiency with MDSZIABC010870 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HICKSTEIN, DENNIS · 2009 to 2025
$18.8M
The Role of microRNA in Hematologic MalignanciesZIACL090025 · CLC · CLINICAL CENTER · PI CALVO, KATHERINE · 2010 to 2025
$0k
Intramural NIH HHS ZIA BC010870Intramural NIH HHS ZIA CL090025
6 · The paper itself

Abstract

GATA2 is a transcription factor critical for hematopoiesis. Germline mutations in GATA binding protein 2 (GATA2) led to haploinsufficiency, severe cytopenias of multiple cell lineages, susceptibility to infections and strong propensity to develop myelodysplastic syndrome, and acute myeloid leukemia. Mechanisms of progressive cytopenias remain unclear. MicroRNA (miRNA) represents a unique mechanism of post-transcriptional gene regulation. In this study, miRNA profiles were evaluated and eight miRNAs were found to be differentially expressed (≥2-fold, P ≤ 0.05) in patient-derived cell lines (N = 13) in comparison to controls (N = 10). miR-9, miR-181a-2-3p, miR-181c, miR-181c-3p, miR-486-3p, and miR-582 showed increased expression, whereas miR-223 and miR-424-3p showed decreased expression. Cell death assays indicated that miR-181c potently induces cell death in lymphoid (Ly-8 and SP-53) and myeloid (HL-60) cell lines. miR-181c was predicted to target myeloid cell leukemia (MCL)1, which was confirmed by transfection assays, resulting in significantly reduced MCL1 mRNA and decreased live cell numbers. Bone marrow analysis of 34 GATA2 patients showed significantly decreased cellularity, CD34-positive cells, monocytes, dendritic cells, NK cells, B cells, and B cell precursors in comparison to healthy controls (N = 29; P < 0.001 for each), which was accompanied by decreased levels of MCL1 (P < 0.05). GATA2 expression led to significant repression of miR-181c expression in transfection experiments. Conversely, knockdown of GATA2 led to increased miR-181c expression. These findings indicate that miR-181c expression is increased and MCL1 levels decreased in GATA2 deficiency cells, and that GATA2 represses miR-181c transcription. Increased miR-181c may contribute to elevated cell death and cytopenia in GATA2 deficiency potentially through down-regulation of MCL1.

Indexed as

GATA2 DeficiencyMicroRNAsMyeloid Cell Leukemia Sequence 1 ProteinCell SurvivalGATA2 Transcription FactorHumansGATA2 protein, humanGATA2 Transcription FactorMCL1 protein, humanMicroRNAsMIRN582 microRNA, humanMyeloid Cell Leukemia Sequence 1 ProteinAMLapoptosisbone marrow failureGATA2immunodeficiencyMCL1MDSmiR-181cmiRNA

Identifiers

PMID34270823
PMCPMC10506419
OpenAlexW3179769212

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.